Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.

1 Jan 2010

Abstract excerpt

BACKGROUND: Around 30% of all stage II colon cancer patients will relapse and die of their disease. At present no objective parameters to identify high-risk stage II colon cancer patients, who will benefit from adjuvant chemotherapy, have been established. With traditional histopathological features definition of high-risk stage II colon cancer patients is inaccurate. Therefore more objective and robust markers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal Cancer Screening and Detection
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic variations and chromosomal abnormalities

Source

Identifiers

PMID: 20966546
DOI: 10.1007/s13402-011-0042-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.PMID 20966546Read ↗

Copy-number intratumor heterogeneity contributes to predict relapse in chemotherapy-naive stage II colon cancerSemantic proximity Read ↗

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.Semantic proximity Read ↗

Prognostic and predictive significance of MSI in stages II/III colon cancer.Semantic proximity Read ↗

Genetic imbalances with impact on survival in colorectal cancer patientsSemantic proximity Read ↗

Impact of chromosomal instability on colorectal cancer progression and outcomeSemantic proximity Read ↗

Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancerSemantic proximity Read ↗

Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trialSemantic proximity Read ↗

Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.Semantic proximity Read ↗

Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.Semantic proximity Read ↗

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.Semantic proximity Read ↗

SOX9 expression predicts relapse of stage II colon cancer patientsSemantic proximity Read ↗

Methylation status in patients with early stage colon cancer: A new prognostic marker?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.